90 results
8-K
EX-99.1
LUMO
Lumos Pharma Inc
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
was promoted to the position of CMO effective January 1, 2024. In this role, Dr. Duke will provide his leadership in Lumos Pharma’s efforts to hone its
8-K
EX-99.2
LUMO
Lumos Pharma Inc
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
. Aaron Schuchart, MBA Chief Business Officer Former Chief Business Officer of Aeglea BioTherapeutics. Former leadership roles in Business Development
8-K
EX-99.1
LUMO
Lumos Pharma Inc
4 Jan 24
Regulation FD Disclosure
4:34pm
. Pitukcheewanont will provide his leadership in Lumos Pharma's efforts to hone its clinical and regulatory strategy, and he will continue to oversee
8-K
EX-99.1
LUMO
Lumos Pharma Inc
15 Nov 23
Other Events
4:38pm
Business Officer Former Chief Business Officer of Aeglea BioTherapeutics. Former leadership roles in Business Development, Strategy, and Finance
8-K
EX-99.2
pvlyhu1v 1qlrjkpg5
14 Nov 22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
6:55am
8-K
EX-99.2
8egyp
10 May 22
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
4:47pm
8-K
EX-99.2
ryt4c6
5 Aug 21
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:27pm
8-K
EX-99.1
hkjl7jiutw4 teg
5 Aug 21
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:27pm
8-K
EX-99.1
2tiqcb
3 Aug 21
Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
9:17am
8-K
EX-99.1
cf7e36
29 Apr 21
Other Events
4:48pm
8-K
EX-99.1
p4zg f0ee
9 Mar 21
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
4:26pm